Product Description: Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research[1][2].
Applications: Cancer-Kinase/protease
Formula: C29H25FN4O5
References: [1]Lynne Canne Bannen, et al. Compounds for the treatment of kinase-dependent disorders. WO2019148044A1./[2]J. Hsu, et al. XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile. European Journal of Cancer, Volume 138, Supplement 2, October 2020, Page S16.
CAS Number: 2367004-54-2
Molecular Weight: 528.53
Compound Purity: 99.73
Research Area: Cancer
Solubility: DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target: c-Met/HGFR;TAM Receptor;VEGFR
Deutsch
English
